Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 11/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916698 | 1.00 | KDM4E (0.54) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14917266 | 0.95 | KDM4E (0.52) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14917265 | 0.95 | KDM4E (0.52) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14925343 | 0.93 | KDM4E (0.54) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14917157 | 0.93 | KDM4E (0.51) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14925345 | 0.93 | KDM4E (0.51) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14917159 | 0.93 | KDM4E (0.51) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14916504 | 0.92 | KDM4E (0.51) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14916505 | 0.92 | KDM4E (0.51) | KDM4EKIF11LMNASTAT3ABCB1 | |
| SCHEMBL14925331 | 0.91 | LMNA (0.59) | KDM4EKIF11LMNASTAT3ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013067409-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | ALCON RESEARCH, LTD. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116219-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | ALCON RESEARCH, LTD. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116219-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | ALCON RESEARCH, LTD. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116219-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | ALCON RESEARCH, LTD. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116219-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | MAVS, OPA1, ZC3HAV1 | KDM4E 2855/4885KIF11 2480/4885LMNA 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.